Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma

Radiology and Oncology

Volumn 41, Issue 1, 2007, Pages

  Novaković, Barbara Jezeršek ^a   Kotnik, Vladimir ^b   Šetina, Tanja Južnič ^a   Vovk, Marjeta ^a   Novaković, Srdjan ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b Faculty of Medicine Ljubljana   (Slovenia)

Author keywords

Antibodies, monoclonal; Antigens, CD 20; Lymphoma, B cell therapy

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34248223056     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-007-0004-y     Document Type: Article

References (15)

1. Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of Lymphoid Malignancies. London: Martin Dunitz Ltd; 2001. p. 153-67.
2. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-43.
3. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
4. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann of Oncol 2003; 14: 520-35.
5. Maloney DG. Mechanisms of action of rituximab. Anticancer Drugs 2001; 12 Suppl 2: S1-S4.
6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.
7. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.
8. Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L, et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother 2005; 54: 273-86.
9. Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. BMC Cancer 2005; 5: 103.
10. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264-76.
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
13. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis. Blood 2000; 95: 3900-8.
14. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-24.
15. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin?s lymphoma. N Engl J Med 1993; 329: 987-94.